Skip to main content

Table 4 Change in vital signs and capillary blood gas parameters with OSNRC or SNC over study periods 1 and 2 of crossover RCT

From: Efficacy and safety of oxygen-sparing nasal reservoir cannula for treatment of pediatric hypoxemic pneumonia in Uganda: a pilot randomized clinical trial

  Perioda,b OSNRC SNC P-valuec
SpO2 (%) 1 − 1 (− 2 to − 0.75) −1.5 (− 2.2 to − 1) 0.44
2 − 1.5 (− 2.8 to − 1) 0 (−1 to 1.2) 0.1
RR (min−1) 1 −2 (− 6 to − 1) 0 (− 7 to 2) 0.7
2 2 (2 to 4) −3 (− 5 to 0.5) 0.1
HR (min−1) 1 −14 (− 16 to − 11) 1 (− 0.25 to 3.5) 0.0086
2 3 (−5.2 to 6) −4 (− 9.8 to 2.8) 0.48
pCO2 (mm Hg) 1 7.5 (5.2 to 7.9) 7.6 (5 to 9.2) 0.79
2 2.2 (1.1 to 3.7) 0.5 (−1.7 to 1.3) 0.11
pH 1 − 0.063 (− 0.073 to − 0.041) − 0.073 (− 0.11 to − 0.035) 0.44
2 − 0.01 (− 0.018 to − 0.0065) 0.0025 (− 0.0092 to 0.0083) 0.34
Lactate (mmol/L) 1 − 0.48 (− 0.72 to − 0.32) 0.33 (− 0.4 to 0.98) 0.028
2 −0.13 (− 0.15 to 0.13) 0.3 (0.1 to 0.43) 0.18
Base excess (mmol/L) 1 0.5 (0 to 2.2) 0 (0 to 0.25) 0.34
2 0.5 (0 to 1) −1 (− 1.2 to 0.25) 0.099
  1. Data represent the median (interquartile range)
  2. aDuring Period 1, patients were treated with OSNRC (Group A, n = 8) or SNC (Group B, n = 8) for 1 hour
  3. bDuring Period 2, patients were treated with OSNRC (Group B, n = 6) or SNC (Group A, n = 8) for 1 hour
  4. cRepresents p-value for difference between OSNRC and SNC treatments